Monoclonal antibodies (mAbs) are now established as targeted therapies for malignancies,
transplant rejection, autoimmune and infectious diseases, as well as a range of new …

Background Steroid‐sparing strategies have been attempted in recent decades to avoid
morbidity from long‐term steroid intake among kidney transplant recipients. Previous …

Since the introduction of pancreas transplantation more than 40 years ago, efforts to develop
more minimally invasive techniques for endocrine replacement therapy have been in …

Objective: To minimize maintenance immunosuppression in upper-extremity transplantation
to favor the risk-benefit balance of this procedure. Background: Despite favorable outcomes …

Transplantation of organs between genetically different individuals of the same species
causes a T cell–mediated immune response that, if left unchecked, results in rejection and …

Remarkable progress has been made in islet transplantation over a span of 40 years. Once
just an experimental curiosity in mice, this therapy has moved forward, and can now provide …

Antilymphocyte therapies are widely used for immunosuppression in solid organ
transplantation. These agents have varied mechanisms of action, with resulting differences …

Background. Alemtuzumab is being increasingly used for the prevention and/or treatment of
acute allograft rejection in organ transplant recipients. We assessed the risks of infection in …

Abstract Introduction CD52 (Campath-1 antigen), a glycoprotein of 12 amino acids anchored
to glycosylphosphatidylinositol, is widely expressed on the cell surface of immune cells …

Solid organ and hematopoietic stem cell transplantation are definitive therapies for a variety
of end-stage diseases. Immunosuppression has improved graft survival but leaves the …